Pharmaceutical industry – Page 43
-
-
Business
Review says cheaper drug is safe for eye disease
Cochrane collaboration says side effects of expensive Lucentis and off-label Avastin are similar
-
Business
Gilead licenses generic hepatitis C drug in India
Company aims to head off competition and grab a slice of royalties
-
Business
Pharma sales ‘will reach $1 trillion’ in 2014
Report predicts continued growth as sales reach an all-time high
-
Business
Cipla targets asthma market with Advair copy
Indian pharma company Cipla has launched a generic version of GSK’s best selling drug
-
Business
Servier to appear in adverts over lack of transparency
Adverts in the medical press will name French pharma firm for failing to comply with disclosure rules
-
Business
Piramal exits drug discovery in India
Company will concentrate on generic medicines and clinical and contract research.
-
Business
Novo Nordisk quits inflammation R&D and cuts jobs
Firm will return to primary focus on diabetes and obesity
-
Business
Exelexis slashes workforce by 70%
Poor clinical trial performance pushes company into cost-cutting drive
-
BusinessRoche to buy InterMune for respiratory boost
$8.3bn deal gives Roche a leading position in pulmonary fibrosis
-
Business
Clinical collaborations drive cancer immunotherapy
Companies race to pair up chemotherapy drugs with immune system-boosting antibodies to greatest effect in trials
-
OpinionDeath of a reagent
Fashion and progress combine to mean some reactions and reagents persist, while others fall by the wayside, says Derek Lowe
-
Business
Sanofi snaps up inhaled insulin licence
Deal gives Mannkind access to global manufacturing and distribution for recently-approved Afrezza
-
Business
Single shot antibiotic approved for skin infections
Third drug in three months approved under US antimicrobials incentive scheme
-
Business
GSK’s China troubles continue
Analysts say stings will only drive corruption into less visible channels
-
BusinessPrice caps provoke lawsuits from Indian pharma industry
New government controls on cardiovascular and diabetes drugs challenged by industry lobby groups
-
Business
Amgen to shed 2400-2900 jobs
Restructuring will see three sites close as company comes under pressure to streamline R&D, despite successes
-
Business
AstraZeneca stocks respiratory and cancer pipelines
A $2bn deal with Almirall and a raft of acquisitions and partnership deals bulk up two focus areas for the company
-
Business
Reckitt Benckiser to spin out US pharma arm
Declining heroin addiction treatment sales prompt divestment as company focuses on over-the-counter and consumer products
-
BusinessTakeover battle pushes Allergan to cut R&D jobs
Besieged by serially acquisitive Valeant, the Botox maker will lay off 1500 staff to propel earnings growth